Physician profile
Stephen Ho
NPI 1497720403
$7,081.24
in general payments reported to CMS, 2019-2025
29 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $373 · 2021: $709 · 2022: $1,407 · 2023: $1,203 · 2024: $1,476 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,571.57 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,577.25 | 2019-2025 | |
| Janssen Biotech, INC. | $646.65 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $568.13 | 2019-2025 | |
| Lilly USA, LLC | $460.45 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $434.46 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $413.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $410.77 | 2020-2025 | Winlevi, Odomzo, Blu-U |
| Galderma Laboratories, L.P. | $333.70 | 2019-2025 | Nemluvio, Oracea |
| Incyte Corporation | $290.88 | 2021-2025 | Opzelura |
| Ucb, INC. | $276.55 | 2021-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $270.34 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $207.07 | 2019-2021 | |
| Amgen INC. | $165.65 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $150.77 | 2022-2023 | Sotyktu |
| Biofrontera INC. | $143.00 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Leo Pharma INC. | $92.83 | 2019-2025 | Anzupgo |
| Vyne Pharmaceuticals INC. | $91.17 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $85.57 | 2023-2025 | Zoryve |
| Organon LLC | $57.41 | 2025 | Vtama |
| Celgene Corporation | $56.27 | 2019 | |
| Epi Health, LLC | $53.08 | 2019 | |
| Dermira, INC. | $47.25 | 2019-2021 | |
| Dermavant Sciences, INC. | $45.72 | 2023-2024 | Vtama |
| Genentech USA, INC. | $39.39 | 2019 | |
| Almirall LLC | $20.28 | 2025 | Klisyri |
| Botanix Sb INC | $16.67 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $14.00 | 2019 | |
| Merck Sharp & Dohme LLC | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.